Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.

Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, Miyagawa T, Yaegashi H, Sano T, Karashima T, Fujita K, Hori JI, Ito T, Kajita M, Tomita Y, Shinohara N, Eto M, Oya M, Uemura H

Open source

DOI: 10.1007/s10147-024-02655-4
Published: 2025 Apr
Container: International journal of clinical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10147-024-02655-4,
  title = {Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.},
  author = {Furukawa J and Kato T and Yamasaki T and Monji K and Tanaka T and Tsuchiya N and Miyagawa T and Yaegashi H and Sano T and Karashima T and Fujita K and Hori JI and Ito T and Kajita M and Tomita Y and Shinohara N and Eto M and Oya M and Uemura H},
  year = {2025},
  journal = {International journal of clinical oncology},
  doi = {10.1007/s10147-024-02655-4},
  url = {https://doi.org/10.1007/s10147-024-02655-4}
}

RIS

TY  - JOUR
TI  - Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.
AU  - Furukawa J
AU  - Kato T
AU  - Yamasaki T
AU  - Monji K
AU  - Tanaka T
AU  - Tsuchiya N
AU  - Miyagawa T
AU  - Yaegashi H
AU  - Sano T
AU  - Karashima T
AU  - Fujita K
AU  - Hori JI
AU  - Ito T
AU  - Kajita M
AU  - Tomita Y
AU  - Shinohara N
AU  - Eto M
AU  - Oya M
AU  - Uemura H
PY  - 2025
JO  - International journal of clinical oncology
DO  - 10.1007/s10147-024-02655-4
UR  - https://doi.org/10.1007/s10147-024-02655-4
ER  -

APA

J, F., T, K., T, Y., K, M., T, T., N, T., T, M., H, Y., T, S., T, K., K, F., JI, H., T, I., M, K., Y, T., N, S., M, E., M, O., & H, U. (2025). Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.. International journal of clinical oncology. https://doi.org/10.1007/s10147-024-02655-4

Source records

pubmed · retrieved 2026-09-27T12:24:38.597Z
europe-pmc · retrieved 2026-09-27T12:24:38.611Z